局部晚期非小细胞肺癌调强质子治疗与被动散射质子治疗的毒性与生存比较
该非随机比较研究纳入139例局部晚期非小细胞肺癌患者,分别接受调强质子治疗(IMPT,53例)或被动散射质子治疗(PSPT,86例)。IMPT组肺、心脏和食管平均剂量更低,≥3级肺毒性和心脏毒性发生率显著更低,但总生存差异仅为趋势。
要点
- IMPT较PSPT降低肺、心脏和食管平均剂量。
- IMPT组≥3级肺毒性和心脏毒性发生率显著更低。
- 两组局部、区域和远处复发率无显著差异。
核心结论
- IMPT与更低的肺、心脏和食管辐射剂量及≥3级心肺毒性发生率相关。
- 两种质子治疗技术的局部、区域和远处复发率无显著差异。
- IMPT组总生存有延长趋势但未达统计学显著,需进一步研究。
研究设计与样本
- 非随机比较研究,纳入两个独立队列的局部晚期NSCLC患者(II-IIIB期,或IV期伴孤立脑转移)。
- 患者接受同步化疗和质子束治疗,共139例,其中PSPT组86例(62%),IMPT组53例(38%)。
- 毒性和结局数据前瞻性收集自临床试验(NCT00915005)或前瞻性登记(NCT00991094)。
主要发现
- IMPT组肺平均剂量13.0 Gy低于PSPT组16.0 Gy(p < 0.001)。
- IMPT组心脏平均剂量6.6 Gy低于PSPT组10.7 Gy(p = 0.004)。
- IMPT组食管平均剂量21.8 Gy低于PSPT组27.4 Gy(p = 0.005)。
- IMPT组≥3级肺毒性发生率2%低于PSPT组17%(p = 0.005)。
- IMPT组≥3级心脏毒性发生率0%低于PSPT组11%(p = 0.01)。
关键数值与推荐
- PSPT组6例(7%)发生4级或5级毒性,IMPT组0例。
- 倾向性评分匹配后,IMPT组肺毒性(3% vs 28%,p = 0.006)和心脏毒性(0% vs 14%,p = 0.05)仍更低。
- IMPT组中位总生存36.2个月,PSPT组23.9个月(p = 0.09)。
- 两组3年局部复发率(20% vs 25%,p = 0.44)、局部区域复发率(36% vs 29%,p = 0.56)和远处复发率(51% vs 52%,p = 0.71)无显著差异。
临床怎么用
- 对于局部晚期NSCLC,IMPT可能较PSPT降低心肺毒性风险。
- 选择质子治疗技术时需权衡毒性获益与生存证据的不确定性。
局限性
- 非随机设计,两组基线可能存在混杂。
- 样本量有限,生存差异检验效能不足。
- 随访时间不同(PSPT组中位23.9个月,IMPT组29.0个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although intensity-modulated radiation therapy (IMPT) is dosimetrically superior to passive scattering proton therapy (PSPT) for locally advanced NSCLC (LA-NSCLC), direct comparisons of clinical outcomes are lacking. Here, we compare toxicity profiles and clinical outcomes after IMPT versus PSPT for LA-NSCLC. METHODS: This is a nonrandomized, comparative study of two independent cohorts with LA-NSCLC (stage II-IIIB, stage IV with solitary brain metastasis) treated with concurrent chemotherapy and proton beam therapy. Toxicity (Common Terminology Criteria for Adverse Events version 4.0) and outcomes were prospectively collected as part of a clinical trial (ClinicalTrials.gov identifier NCT00915005) or prospective registry (ClinicalTrials.gov identifier NCT00991094). RESULTS: Of 139 patients, 86 (62%) received PSPT and 53 (38%) IMPT; median follow-up times were 23.9 and 29.0 months, respectively. IMPT delivered lower mean radiation doses to the lungs (PSPT 16.0 Gy versus IMPT 13.0 Gy, p < 0.001), heart (10.7 Gy versus 6.6 Gy, p = 0.004), and esophagus (27.4 Gy versus 21.8 Gy, p = 0.005). Consequently, the IMPT cohort had lower rates of grade 3 or higher pulmonary (17% versus 2%, p = 0.005) and cardiac (11% versus 0%, p = 0.01) toxicities. Six patients (7%) with PSPT and zero patients (0%) with IMPT experienced grade 4 or 5 toxicity. Lower rates of pulmonary (28% versus 3%, p = 0.006) and cardiac (14% versus 0%, p = 0.05) toxicities were observed in the IMPT cohort even after propensity score matching for baseline imbalances. There was also a trend toward longer median overall survival in the IMPT group (23.9 mo versus 36.2 mo, p = 0.09). No difference was found in the 3-year rates of local (25% versus 20%, p = 0.44), local-regional (29% versus 36%, p = 0.56) and distant (52% versus 51%, p = 0.71) recurrences. CONCLUSIONS: IMPT is associated with lower radiation doses to the lung, heart, and esophagus, and lower rates of grade 3 or higher cardiopulmonary toxicity; additional clinical studies will be needed to assess the potential differences in survival between the two techniques.
引用
- Gjyshi O, Xu T, Elhammali A, et al. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol. 2020. PMID: 33198942. doi:10.1016/j.jtho.2020.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。